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 Community-acquired pneumonia (CAP) is the leading cause of 
death from infection in developed countries. There is evidence 
of an association between improved survival from infection and 
statin use. The possible beneﬁ cial effects of statins are compli-
cated by the common use of macrolide antibiotics for pneumo-
nia, with current guidance suggesting that concurrent macrolide 
and statin use is contraindicated.  We conducted an observational 
study of statin use in patients with CAP. Of 2,067 patients with 
CAP, 30.4% were on statin therapy at admission. Statin users 
were more likely to survive the admission (p<0.001). In addition, 
we conducted a survey of doctors and found that knowledge 
regarding concurrent macrolide and statin use was lacking.  These 
data suggest a potential role of statins in the management of 
CAP. Further research using high-dose statins is required to assess 
their safe use in subjects with mild to moderate infections. 
 KEYWORDS :  Immunomodulatory drugs ,  macrolide antibiotic , 
 pneumonia ,  sepsis ,  statin 
 Introduction 
 Pneumonia is the leading cause of infectious death in 
developed countries, and mortality rates have not improved 
in the last decade. 1 Patients admitted to hospital with 
community-acquired pneumonia (CAP) have approximately 
20% mortality, rising to 35% if they develop sepsis and 
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45% if they develop multi-organ failure. 2 It is predicted that 
hospitalisation for CAP may double by 2040. 3 
 Although inflammation is a necessary physiological 
response to infection, it has been suggested that an excessive 
and dysregulated inflammatory response contributes to the 
pathology and hence morbidity and mortality seen in CAP. 4 
Multiple trials have attempted to modulate this excessive 
immune response using corticosteroids and other drugs, but 
none have demonstrated significant benefit. 5 With a dearth 
of novel drug development for infection in recent years, 
increasingly efforts have focused on repurposing established 
drugs and investigating their possible immunomodulatory 
effects. 
 HMG-CoA reductase inhibitors (statins) competitively inhibit 
HMG-CoA reductase, the first enzyme active in the mevalonate 
pathway, and are the most commonly prescribed drugs in the 
UK. 6 They are conventionally used as cholesterol lowering 
agents; however, a number of population studies and clinical 
trials have suggested survival benefits during infection 7–10 and 
pre-dosing with statins improves outcomes in murine sepsis 
models. 11 Inhibition of the mevalonate pathway results in 
reduced production of isoprenoids, which are required for the 
function of small GTP-ases and therefore essential for innate 
and adaptive immunity pathways. 12–14 Suggested beneficial 
effects of statins include improved neutrophil function, 15,16 
decreased inflammatory cell influx into the lungs, 17 reduced 
pro-inflammatory cytokine release, 17,18 prevention of T-cell 
activation 19 and reduction of local and systemic levels of 
C-reactive protein (CRP). 20 Based on this, preclinical and 
observational studies have been performed and suggest a 
benefit in those with infection; however, these findings have not 
translated to positive outcomes in randomised controlled trials 
(RCTs) of established severe sepsis or acute respiratory distress 
syndrome. The reasons for this remain unclear. 
 There is no clear guidance on whether statins should be 
continued on admission to hospital with infection. A single 
study examined the benefits of continued statin therapy or 
placebo in critically ill patients and found no difference in 
survival or progression of sepsis. 21 
 The National Institute for Health and Care Excellence (NICE) 
guidance suggests that all patients with either moderate or 
severe CAP should receive a macrolide antibiotic in addition 
to either amoxicillin or a beta-lactam antibiotic. 22 Commonly, 
clarithromycin is used as the macrolide component, which 
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is a potent enzyme inhibitor. Medicines and Healthcare 
products Regulatory Agency (MHRA) guidance suggests statins 
should not be concurrently administered with clarithromycin 
because of the risk of rhabdomyolysis and acute renal failure. 23 
The absolute risk of acute kidney injury caused by statin 
and clarithromycin co-treatment was 0.02%, although this 
represents a relative risk of 2.06 compared with concurrent 
statin and azithromycin treatment. 24 In UK hospital practice, 
macrolide-statin co-prescription is monitored as an indicator of 
prescribing safety and as a result a large proportion of patients 
have statin therapy paused on admission. 25 With conflicting 
data in the literature and the issues surrounding macrolide-
statin co-prescription, it remains unclear whether statins are of 
benefit to those with CAP. 
 We therefore undertook a retrospective study to assess the 
association of statin therapy at hospital admission with clinical 
outcomes for CAP. In addition, knowledge of macrolide-statin 
co-prescription guidance among the consultant and training-
grade doctors in a large teaching hospital was evaluated. 
 Methods 
 Study institution and CAP subjects 
 All adults admitted with CAP to the University Hospitals 
Birmingham NHS Foundation Trust (UHB) between October 
2009 and November 2011 were eligible for inclusion. These 
patients were identified using the hospital’s coding system, 
using pre-defined ICD-10 codes (J12–16, 18). UHB is a large, 
tertiary centre teaching hospital in the West Midlands, UK, 
which admits unselected adults for acute medical care. 
 CAP was defined as an acute lower respiratory tract illness 
associated with new radiographic shadowing for which there 
was no other explanation, in accordance with British Thoracic 
Society guidelines. 26 The radiographs and clinical notes of 
all patients eligible for inclusion underwent clinical review 
to confirm the diagnosis. As a marker of CAP severity, the 
CURB-65 score was calculated. Using electronic patient records 
the following data were captured: age, gender, diagnosis of 
diabetes mellitus, length of hospital admission, intensive care 
unit (ICU) admission, ICU length of stay, CRP, white cell count 
(WCC), urea and statin use (defined as a statin prescription 
within 24 hours of admission). The primary outcome measure 
was inpatient mortality. Secondary outcome measures included 
length of hospital stay, ICU admission and ICU length of stay. 
 Macrolide-statin co-prescription surveys 
 We devised an online survey to evaluate the knowledge of 
consultant and training-grade doctors working at the same trust 
the study was conducted in (UHB). The survey was designed 
using Survey Monkey TM (Oregon, USA) and emailed to all 
doctors attending the Clinical Grand Round in November 2016. 
 The survey asked the following four questions: 
 1 What grade are you? (Junior doctor/Consultant) 
 2 Are you aware of any drug interactions with clarithromycin? 
(Yes/No) 
 3 Are you aware of an interaction between statins and 
 clarithromycin? (Yes/No) 
 4 Do you pause statins when prescribing clarithromycin? 
(Yes/No/Sometimes) 
 Statistical analysis 
 Normality was assessed using the Kologmorov-Smirnov test. 
Statin-users and non-users were compared using the Mann-
Whitney-U test when variables were continuous and χ2-test for 
categorical variables. Logistic regression was used to calculate a 
predicted probability of death and evaluate the effects of statin 
therapy on the predicted survival from pneumonia. This was 
done using a model taking into account age and statin therapy 
in the first instance. This model was then refined to correct 
for gender, diabetic status and CRP. Significance was accepted 
at p<0.05. Survey data were analysed using a Chi-squared 
test. Statistical analyses were carried out using PASW v18.0 
(Chicago, IL, USA). 
 Results 
 A total of 2,225 patients were identified as having CAP by the 
hospital coding system. In total, 2,067 patient episodes were 
included for final analysis; of these, 633 were taking a statin 
on admission and 1,434 were not (Fig  1 ). Simvastatin was the 
most commonly used statin (75.5%), followed by atorvastatin 
(19.4%), fluvastatin (4.7%) and rosuvastatin (0.2%). 
 Demographics and clinical characteristics of patients 
 Approximately half of patients were male (50.6%), with a mean 
age (SD) of 71.2 years (18.2). Statin users were older (statin user 
versus non-user: mean ± SD 75.6±11.7 years versus 69.2±20.1 
years, p<0.001) and had a higher prevalence of diabetes (statin 
user versus non-user: 36.4% versus 12.1%, p<0.001). Statin 
Paents coded as CAP between
October 2009 and November 2011
n=2,225
157 paents excluded from
ﬁnal study populaon:
137 did not meet BTS
diagnosc criteria aer clinical
review
21 had a clinical diagnosis of
viral or fungal pneumonia
Clinical diagnosis of
bacterial or unspeciﬁed
pneumonia
n=2,067
Not taking a stan
n=1,434
Taking a stan
n=633
 Fig 1.  Modiﬁ ed CONSORT diagram demonstrating patient inclusion 
pathways and reasons for exclusion. BTS = British Thoracic Society; 
CAP = community-acquired pneumonia; CONSORT = Consolidated Standards 
of Reporting Trials. 
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users had higher urea (p≤0.005) and were more likely to be 
male (p<0.001) (Table  1 ). 
 In-hospital mortality 
 In terms of in-hospital mortality, survival was significantly 
higher among statin users (statin user 83.1% versus non-user 
75.5%, p<0.0001). 
 Using logistic regression, predicted probability of in-hospital 
death was calculated, while controlling for age and gender (Fig  2 ). 
The odds ratio (OR) for in-hospital death from pneumonia was 
1.046 (p<0.001, 95% CI 1.038–1.054) for each additional year 
of age. The OR for in-hospital death was higher in males (1.249, 
p<0.001, CI 1.003–1.556). When taking a statin, the OR for in-
hospital death was reduced to 0.515 (p<0.001, CI 0.403–0.660). 
 After adjusting for disease severity (as assessed by CURB-
65 score), age, diabetes and CRP, outcomes were better in 
patients on higher doses of simvastatin (Table  2 ). There was 
no statistically significant benefit, in terms of OR for in-
hospital mortality, in those who received a simvastatin dose 
above 40 mg. The class of statin administered had no effect on 
mortality (data not shown). 
 Secondary outcome measures 
 Statin users had increased length of hospital stay (statin user 
versus non-user 13.5 days versus 8.7 days, p<0.001) and were 
more likely to be admitted to the ICU (statin user 10.6% versus 
non-user 7.1%, p=0.008). Although there was a statistically 
significant difference in CURB-65 score, the two groups were 
clinically comparable. There was no difference in WCC or CRP 
between the two groups (Table  1 ). 
 Survey of knowledge regarding statin and macrolide 
antibiotics 
 One hundred responses were submitted using the free online 
survey software; 61 consultants (61%) and 39 trainees (39%). 
Of those who responded to the survey, 84% were aware of drug 
interactions with clarithromycin and 72% were aware of the 
 Table 1.  Cohort characteristics 
 Statin user n=633 Non-user n=1,434 Total, n (%) p-value 
n (%) 633 (30.7) 1,434 (69.3) 2,067
 Mean age ± SD, years 75.66±11.7 69.2±20.1 <0.001
 Gender , n (%)
 Male 355 (56.2) 691 (48.2) 1,046 (50.6) 0.001
 Female 278 (43.8) 743 (51.8) 1,021 (49.4)
 Patient outcome , n (%)
 Survived 526 (83.1) 1,083 (75.5) 1,609 (77.9) <0.001
 Died 107 (16.9) 351 (24.5) 458 (22.1)
 Diabetes status , n (%)
 Yes 230 (36.4) 174 (12.1) 404 (19.6) <0.001
 No 403 (63.6) 1,260 (87.9) 1,663 (80.4)
 Mean length of stay ± SD, days 13.5±15.2 8.7±12.7 <0.001
 ICU admission , n (%)
 Yes 67 (10.6) 102 (7.1) 169 (8.1) 0.008
 No 567 (89.4) 1,331 (92.9) 1,898 (91.9)
 Mean ICU length of stay ± SD, days 8.6±10.3 7.7±8.9 169 (8.1) 0.483
 Median CURB-65 score (IQR) 2 (2–2) 2 (1–3) 2,006 (97) <0.001
 Median CRP median, mg/L (IQR) 93 (34–211) 102 (43–215) 1,801 (87) 0.188
 Median WCC , ×10 9 /L (IQR) 12.8 (9.3–16.5) 12.6 (8.9–16.9) 1,573 (76) 0.709
 Median urea , mmol/L (IQR) 8.6 (6.1–12.3) 7.3 (4.9–11.3) 2,006 (97) <0.001
 CRP = C-reactive protein; ICU = intensive care unit; IQR = interquartile range; SD = standard deviation; WCC = white cell count 
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 Fig 2.  Relationship between predicted probability and death and in-
creasing age. Stratiﬁ ed according to statin users and non-users, and gender. 
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specific interaction between statins and clarithromycin. When 
asked if they pause statin therapy for the duration of macrolide 
treatment responses varied with 40% responding ‘yes’, 31% ‘no’ 
and 29% ‘sometimes’. 
 When stratified according to training grade, trainee doctors 
were more likely to be aware of the drug interactions than 
consultants (p=0.039) and were more likely to always pause 
statin therapy when prescribing a macrolide antibiotic (p=0.02). 
 Discussion 
 Our data suggest that patients with CAP who are taking a statin 
on admission have reduced risk of in-patient mortality. This is 
despite being older, having increased length of hospital stay and 
increased likelihood of requiring ICU admission. 
 Despite clear MHRA guidance regarding concurrent statin 
and macrolide prescription, we have demonstrated that 
knowledge and practice in this area is lacking. With increasing 
numbers of patients expected to start taking statins, this is set 
to become a more frequent clinical issue. 
 The mechanism by which statins reduce risk of in-patient 
death in this cohort remains unclear. Statins influence multiple 
anti-inflammatory pathways;  12–14 it may be that stopping statin 
therapy at a time of hyper-inflammation could cause rebound 
inflammation and adversely affect patient outcomes. There 
is also evidence to suggest that statins are able to modulate 
immune cell function, which could reduce the damaging 
inflammation associated with organ dysfunction. Alternatively, 
it is estimated that cardiovascular events account for up to 30% 
of the mortality associated with CAP, and hence the beneficial 
effect we have observed could be directly related to the lipid-
lowering effects and plaque stabilisation. 27 
 Despite promising observational studies and animal model 
data, no RCT to date has demonstrated a beneficial effect from 
statin therapy in established sepsis. There is no consensus as 
to why this may be.  In vitro cellular studies often utilise statin 
concentrations that exceed standard prescribing regimens while 
RCTs have often used low-dose statins. 28 In addition, RCTs are 
often carried out in patients of varying age with established 
sepsis on short-term therapy while population studies have 
included older patients who were taking statins prior to the 
infective event, as is the case in our study. 28 This may suggest 
that timing of statin therapy is important or that statins are 
not beneficial at the stage of severe sepsis but may have greater 
utility in mild infection 29 and in preventing progression to 
severe sepsis. In keeping with this, atorvastatin has been shown 
to prevent the progression of mild ward-based sepsis patients to 
severe sepsis in an interventional trial. 30 
 It may also be the case that statins are not an effective therapy 
for all septic patients and further work needs to be completed to 
identify patient groups who would benefit from this potentially 
immunomodulatory therapy. Furthermore, the dose of statin 
used in the RCTs has been heterogeneous; it may be that high 
doses of statins are required prior to the onset of severe sepsis. 
In the current retrospective study, the higher doses of statins 
were associated with the greatest in hospital survival benefit. 
 In the UK, admission to the ICU is dependent on severity of 
the acute illness, identification of a reversible cause, as well as 
the physiological reserve of the patient prior to illness onset. 
Increased rates of ICU admission among statin users in this 
study may seem to suggest increased severity of pneumonia and 
sepsis. However, there was no clinical difference in the severity 
of pneumonia between statin using and non-using adults in the 
current study and therefore it may also be the case that statin 
users have greater physiological reserve and hence are more 
likely to be accepted for ICU admission. 
 Length of hospital stay is also related to severity of illness, 
physiological capacity for recovery as well as provision of social 
support on discharge. The increased length of stay among 
statin users may again indicate that these patients either had 
more severe pneumonia (which we did not find) or a prolonged 
recovery period. Our analysis included the length of stay of 
all patients, whether they died in hospital or not; those who 
survived may have had longer hospital stays. 
 Statins are commonly prescribed at present but are set to 
become almost ubiquitous given new NICE guidance. 31 Our 
data suggest that statins are beneficial in CAP, but the risk 
versus benefit ratio in co-prescription of statins and macrolides 
may need to be evaluated. 
 Our study has limitations; it is a retrospective design, which 
limits our ability to account for confounders, although we 
have demonstrated that the severity of pneumonia was similar 
across the two groups. We cannot demonstrate causality 
and healthcare-seeking behaviours must be considered 
as an important confounding factor. The timing of statin 
administration and dose of statin seems to be crucial in their 
beneficial effect as demonstrated by the divergent evidence 
from existing population studies, RCTs and this study. We 
used the hospital’s electronic patient record for mortality data, 
which has inaccuracies in outpatient mortality as well as cause 
of death data. Given this, we reported inpatient death and all-
cause mortality as outcomes, which may have introduced bias. 
 Table 2.  Relationship between simvastatin dose and mortality 
 n B SE OR (95% CI) p-value 
Simvastatin dose
10 mg 15 4.346 0.825 77.189 (15.331–388.634) <0.001
20 mg 76 3.019 0.351 20.472 (10.285–40.747) <0.001
40 mg 352
80 mg 36 –1.003 1.054 0.367 (0.046–2.893) 0.341
 Relationship assessed by logistic regression and adjusted for age and disease severity (CURB-65 score). To assess the effect on mortality of increasing doses of 
simvastatin, patients taking 10 mg, 20 mg and 80 mg were compared to those on 40 mg. 
 B = regression coefficient; CI = confidence interval; OR = odds ratio; SE = standard error 
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 Conclusions 
 Statin use at the time of hospital admission is associated with 
lower in-hospital mortality in CAP, despite older age of patients 
and higher burden of diabetes. RCTs are yet to show conclusive 
benefits of statins in sepsis; this may be due to the timing of 
statin administration, dose heterogeneity or statins being 
ineffective once sepsis is established. 
 Further RCTs of statins in mild to moderate infections are 
warranted, with particular efforts to identify patient characteristics 
linked to benefit from immunomodulatory therapy. ■ 
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